Using 5-fluorouracil to treat Basal Cell Carcinoma
The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma: Clinical Trail
This study is testing if a medication called 5-fluorouracil can safely and effectively treat certain types of Basal Cell Carcinoma without surgery.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Sex | All |
| Sponsor | University of Aleppo Academic / other |
| Locations | 1 site (Aleppo) |
| Trial ID | NCT06150144 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and efficacy of intralesional 5-fluorouracil (5-FU) for treating various types of Basal Cell Carcinoma (BCC), excluding infiltrative types. Patients will be randomly selected from the outpatient dermatologic clinic at Aleppo University Hospital and monitored over a 24-month period. The study aims to provide evidence for 5-FU as a cost-effective alternative to surgical excision, building on previous findings that suggest its potential effectiveness. The outcomes will be assessed to determine the viability of this treatment approach for BCC management.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 5 to 90 with superficial or nodular BCC lesions measuring 1.5 cm or less.
Not a fit: Patients with ulcerative lesions or nodular lesions larger than 1.5 cm may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a less invasive and cost-effective alternative to surgical excision for patients with Basal Cell Carcinoma.
How similar studies have performed: While some studies have shown positive results for 5-FU in treating superficial BCC, the intralesional administration for other types has not been thoroughly assessed, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 5 Years to 90 Years (Child, Adult, Older Adult). * Volunteer to participate in study * Superficial lesion * Nodular lesion (x ≤ 1.5 cm) patients are seen at the outpatient Department or in the dermatology wards at Aleppo University Hospital (AUH) over 12 months' period. Exclusion Criteria: * Ulcerative. * Nodular lesion (x ≥ 1.5 cm)
Where this trial is running
Aleppo
- Ibrahim Arnaout — Aleppo, Syrian Arab Republic (Recruiting)
Study contacts
- Principal investigator: Noura Abdulrahman, M.D. — Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria
- Study coordinator: Ibrahim Arnaout, M.D. Candidate
- Email: ibrahim.arnaout25@gmail.com
- Phone: +963993279977
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.